Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06643884 · ClinicalTrials.gov registry record · Phase 2
Suprachoroidal Administration in Subjects With Metastases to the Choroid
A Phase 2 study of Eye Cancer and Primary Cancer, sponsored by Aura Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 10
- Study locations
NCT06643884: Recruiting Phase 2 study of Eye Cancer and Primary Cancer, sponsored by Aura Biosciences.
NCT06643884 is a Phase 2 study of Eye Cancer and Primary Cancer that is actively recruiting participants, run by Aura Biosciences. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06643884, a Phase 2 study of Eye Cancer and Primary Cancer, is actively recruiting participants, sponsored by Aura Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 10
- Study locations
Study Summary
The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
Primary Outcome
B-Scan Ultrasonography
Conditions Studied
Interventions
- DRUG AU-011
- DEVICE SCS Microinjector
- DEVICE Laser
Study Locations (10)
California
- Byers Eye Institute at Stanford University - Palo Alto
Florida
- Bascom Palmer Eye Institute - Miami
Massachusetts
- Massachusetts Eye and Ear - Boston
Michigan
- Kellogg Eye Center - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic, Cole Eye Institute - Cleveland
Pennsylvania
- Shields and Shields, PC - Philadelphia
Tennessee
- Tennessee Retina, PC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 2 |
What NCT06643884 shows while recruiting
NCT06643884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Eye Cancer appearing as the primary indexed condition, and to 3 interventions - of which AU-011 is the first listed.
NCT06643884 lists 10 locations in 10 states (California, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06643884 about?
NCT06643884 is a clinical study titled "Suprachoroidal Administration in Subjects With Metastases to the Choroid". The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.
What is the current status of trial NCT06643884?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2024-12-16. Estimated completion is 2027-10-31.
What conditions does trial NCT06643884 study?
This clinical trial studies the following conditions: Eye Cancer, Primary Cancer.
What interventions are being tested in trial NCT06643884?
The interventions under investigation include: AU-011 (DRUG), SCS Microinjector (DEVICE), Laser (DEVICE).
Who is sponsoring clinical trial NCT06643884?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06643884 being conducted?
This trial has 10 study locations across California, Florida, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06643884's enrollment target sits among peer trials
24 1756th of 2000 higher than 218 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI